# A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

> **NCT05214976** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 64 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)

## Key facts

- **NCT ID:** NCT05214976
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-12
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05214976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05214976, "A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05214976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*